Our use of cookies

We use necessary cookies to make our site work.

For more detailed information about the cookies we use, see our Cookie Policy.


Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Transparency Sweden

Otsuka Pharma Scandinavia AB (OPSAB) is a subsidiary of Otsuka Pharmaceutical Europe Ltd (OPEL) who is a member of the national pharmaceutical industry associations in the Nordic region (Läkemedelsindustriföreningen (LIF), Legemiddelindustrien (LMI)) which incorporates the EFPIA disclosure code as part of the national codes in the Nordic region. As such Otsuka Pharma Scandinavia AB (OPSAB) agrees to publically disclose certain transfers of value made directly or indirectly to healthcare professionals and healthcare organisations. This includes, but is not limited to:
  • Travel and accommodation
  • Fee for services and all consultancy
  • Any agreement related expenses or benefits (e.g. taxi, out of pocket expenses)
  • Contribution towards events and costs of meetings paid to healthcare organisations
  • Grants and donations
  • Research and development (in aggregate)
 Where an HCP has not granted consent to disclosure on an individually named basis, these transfers of value are reported in aggregate. Otsuka Pharma Scandinavia AB (OPSAB) disclosure data and details on the methodology used to prepare the data can be found in the links below. Any questions relating to this information should be directed to .
Otsuka Pharma Scandinavia AB (OPSAB) är ett dotterbolag till Otsuka Pharmaceutical Europe Ltd (OPEL) och medlem i de nationella läkemedelsindustriföreningarna i Norden (Läkemedelsindustriföreningen (LIF), Legemiddelindustrien (LMI)) vilka införlivat EFPIA disclosure code i de nationella koderna I Norden. OPSAB samtycker till att offentliggöra vissa värdeöverföringar som gjorts direkt eller indirekt till hälso- och sjukvårdpersonal samt övrig hälso- och sjukvård. Dessa inbegriper, men är inte begränsade till:
  • Arvode och konsulttjänster
  • Resor och boende
  • Avtalsrelaterade utgifter eller förmåner (t ex taxi, andra utlägg)
  • Bidrag till aktiviteter och möteskostnader utbetalade till hälso- och sjukvård
  • Donationer
  • Forskning och utveckling (rapporteras I aggregerad form)
  • När en HCP inte gett sitt samtycke till publicering på individnivå kommer de aktuella värdeöverföringarna att rapporteras I aggregerad form 
Otsuka Pharma Scandinavia AB (OPSAB) information om ersättningar till hälso och sjukvården samt detaljer om metodiken som används för att förbereda data finns i länkarna nedan. Eventuella frågor som rör denna information ska riktas till . DISCLAIMER
  • The publication of this data is necessary in order to comply with the transparency obligations arising from the EFPIA code
  • Access to the website of Otsuka Pharmaceutical Europe Ltd or any of its affiliate companies does not grant any right to use the disclosed data for any purpose whatsoever.
  • Otsuka Pharmaceutical Europe Ltd and its affiliates have taken reasonable steps in order to avoid indexation of the data on this website through public search engines.

Date of preparation: January 2021 | Reference NOR-NPR-2100001

This website is for all those with an interest in Otsuka Pharmaceutical in the Nordics and BeNeLux.